1)Liu Q, Hu Y, Yu H et al:Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema. Retina 35:272-279, 2015
2)Bhayana S, Sood S, Narang S et al:Intravitreal bevacizumab versus posterior subtenon triamcinolone in diffuse diabetic macular edema. Int Ophthalmol 2014 Aug 12[Epub ahead of print]
3)Lee SJ, Kim ES, Geroski DH et al:Pharmacokinetics of intraocular drug delivery of Oregon green 488-labeled triamcinolone by subtenon injection using ocular fluorophotometry in rabbit eyes. Invest Ophthalmol Vis Sci 49:4506-4514, 2008
4)島田佳明・米谷 新:脈絡膜の血管構造と血流.大鹿哲郎:眼科臨床に必要な解剖生理,248-253,文光堂,東京,2005
5)Shimura M, Yasuda K, Nakazawa T et al:Visual outcome after intravitreal triamcinolone acetonide depends on optical coherence tomographic patterns in patients with diffuse diabetic macular edema. Retina 31:748-754, 2011
6)Arévalo JF, Fernández CF, Mendoza AJ et al:Intravitreal triamcinolone combined with grid laser photocoagulation for patients with cystoid macular edema and advanced diabetic retinopathy:pilot study. Arch Soc Esp Oftalmol 88:373-379, 2013
7)Sonoda S, Sakamoto T, Yamashita T et al:Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema. Retina 34:741-748, 2014
8)Sonoda S, Sakamoto T, Yamashita T et al:Effect of intravitreal triamcinolone acetonide or bevacizumab on choroidal thickness in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 55:3979-3985, 2014
9)Horii T, Murakami T Akagi T, et al:Optical coherence tomographic reflectivity of cystoid spaces is related to recurrent diabetic macular edema after triamcinolone. Retina 35:264-271, 2015
10)Qi HP, Bi S, Wei SQ et al:Intravitreal versus subtenon triamcinolone acetonide injection for diabetic macular edema:a systematic review and meta-analysis. Curr Eye Res 37:1136-1147, 2012
11)Audren F, Lecleire-Collet A, Erginay A et al:Intravitreal triamcinolone acetonide for diffuse diabetic macular edema:phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol 142:794-799, 2006
12)Yilmaz T, Weaver CD, Gallagher MJ et al:Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema:a systematic review. Ophthalmology 116:902-911, 2009
13)Entezari M, Ahmadieh H, Dehghan MH et al:Posterior sub-tenon triamcinolone for refractory diabetic macular edema:a randomized clinical trial. Eur J Ophthalmol 15:746-750, 2005
14)Cheema HR, Al Habash A, Al Askar E:Improvement of visual acuity based on optical coherence tomography patterns following intravitreal bevacizumab treatment in patients with diabetic macular edema. Int J Ophthalmol 7:251-255, 2014
). Int Ophthalmol 34:971-977, 2014
16)Hirano Y, Ito T, Nozaki M et al:Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes. Jpn J Ophthalmol 53:519-522, 2009
17)Azad R, Sain S, Sharma YR et al:Comparison of intravitreal bevacizumab, intravitreal triamcinolone acetonide, and macular grid augmentation in refractory diffuse diabetic macular edema:a prospective, randomized study. Oman J Ophthalmol 5:166-170, 2012
18)村田敏規:矯正視力1.0を目指せる糖尿病黄斑浮腫の治療.日本の眼科 84:1354-1359, 2013
19)Kriechbaum K, Prager S, Mylonas G et al:Intravitreal bevacizumab(Avastin)versus triamcinolone(Volon A)for treatment of diabetic macular edema:one-year results. Diabetic Retinopathy Research Group. Eye(Lond) 28:9-15, 2014
20)García Fernández M, García Alonso A, Fonollá Gil M et al:Intravitreal triamcinolone acetonide use in diffuse persistent diabetic macular edema. Arch Soc Esp Oftalmol 86:314-319, 2011